Navigation Links
Potential new therapeutic molecular target to fight cancer
Date:11/1/2007

Researchers at the Virginia Commonwealth University Massey Cancer Center have identified the enzyme sphingosine kinase 2 as a possible new therapeutic target to improve the efficacy of chemotherapy for colon and breast cancer.

In the Nov. 1 issue of the journal Cancer Research, researchers examined human colon and breast cancer cells and established a role of sphingosine kinase 2 (SphK2), an enzyme that forms the potent lipid mediator sphingosine-1-phosphate in the death of cancer cells mediated by the chemotherapeutic drug, doxorubicin.

Doxorubicin is able to kill cancer cells by working with p53, one of the most protective anti-cancer proteins in the human body. However, doxorubicin also relies on p53- independent mechanisms to induce death in colon and breast cancer cells.

Understanding how doxorubicin kills in a p53-independent manner is a major goal of cancer researchers because most cancer cells have mutated p53, said lead author Sarah Spiegel, Ph.D., chair and professor in the VCU Department of Biochemistry and Molecular Biology and co-leader of the cancer center's cancer cell biology program.

According to Spiegel, the study demonstrated that SphK2 is important for p53-independent induction of expression of p21, a cyclin-dependent kinase inhibitor. This p21 regulates the cell cycle, and apoptosis or programmed cell suicide, mediated by doxorubicin. Human colon and breast cancer cells were killed more efficiently by doxorubicin when SphK2 was removed from the cells.

Therefore, the findings suggest that SphK2 influences the balance between cytostasis, and apoptosis of human cancer cells, Spiegel said. Cytostasis refers to the stoppage of cellular growth and multiplication.

Spiegel said that cell death was induced by doxorubicin and decreased p21.

Spiegel, who is internationally recognized for her pioneering work on new lipid mediators that regulate cell growth and cell death, and her colleagues, first discovered the role of sphingosine-1-phosphate in cell growth regulation nearly a decade ago. Spiegel and her team are continuing this work to better understand the functions of these enzymes.


'/>"/>

Contact: Sathya Achia-Abraham
sbachia@vcu.edu
804-827-0890
Virginia Commonwealth University
Source:Eurekalert

Related biology news :

1. Novel Enzyme Shows Potential As An Anti-HIV Target
2. Potential Cure for Lymphoma in HIV patients
3. MetaChip provides quick, efficient toxicity screening of potential drugs
4. Simple drug has the potential to save many lives threatened by malaria
5. Potential treatments for neurofibromatosis
6. Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks
7. Potential Drug Target For Treating Cocaine Abuse Found
8. Scripps scientists find potential for catastrophic shifts in Pacific ecosystems
9. Engineers improve plastics potential for use in implants by linking it to biological material
10. Human embryonic stem cells have the potential to develop into eggs and sperm in the laboratory
11. Improving the potential of cancer vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
(Date:2/9/2017)... -- The biomass boiler market report by Transparency Market ... globally in terms of revenue (US$ Mn) based on ... biomass boilers has been segmented on the basis of ... market based on feedstock type, has been segmented into ... crops, urban residues, and others. On the basis of ...
(Date:2/8/2017)... 7, 2017 Report Highlights ... The global synthetic-biology market reached ... by 2021, growing at a compound annual growth rate (CAGR) ... of the global markets for synthetic biology. - Analyses of ... and projections of compound annual growth rates (CAGRs) through 2021. ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers ... from small lab samples to full-size tissues, bones, even whole organs to implant ... system that delivers blood deep into the developing tissue. , Current bioengineering ...
(Date:3/22/2017)... , March 22, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage ... drug delivery systems, announced today that Dr. ... deliver a presentation titled, "Oral Insulin for Diabetes ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced Tallahassee, ... their live events series, “Stem Cell Therapy: The Next Phase in the Evolution of ... Stem Cell Research and Therapy Act, Okyanos maintains a mission to help ...
Breaking Biology Technology: